Table 1 Baseline characteristics of the study population (n = 531)
Demographic & clinical factors | |
Age, y [IQR] | 69 [60–78] |
Sex, male, n (%) | 352 (66.3) |
Visit time, h [IQR] | 6.1 [1.8–20.8] |
Hypertension, n (%) | 360 (67.8) |
Diabetes, n (%) | 196 (36.9) |
Dyslipidemia, n (%) | 278 (52.4) |
Atrial fibrillation, n (%) | 88 (16.6) |
Ischemic heart disease, n (%) | 57 (10.7) |
Chronic kidney disease, n (%) | 54 (10.2) |
Current smoking, n (%) | 138 (26.0) |
Initial NIHSS score, [IQR] | 3 [2-7] |
Stroke mechanism, n (%) | |
Large artery atherosclerosis | 154 (29.0) |
Small vessel occlusion | 140 (26.4) |
Cardioembolism | 116 (21.8) |
Other determined | 13 (2.4) |
Undetermined | 108 (20.3) |
Thrombolytic therapy, n (%) | 76 (14.3) |
Laboratory factors | |
Hemoglobin A1c, % [IQR] | 5.9 [5.6–6.6] |
Fasting glucose, mg/dL [IQR] | 117 [98–153] |
Glycated albumin, % [IQR] | 14.7 [13.1–17.0] |
LDL cholesterol, mg/dL [IQR] | 97 [73–126] |
HDL cholesterol, mg/dL [IQR] | 43 [37–51] |
Triglyceride, mg/dL [IQR] | 100 [73–145] |
White blood cell counts, x 103/uL [IQR] | 7.5 [6.1–9.4] |
High-sensitivity C-reactive protein, mg/dL [IQR] | 0.98 [0.32–2.57] |
Outcome variables | |
Early neurological deterioration, n (%) | 96 (18.1) |
Discharge mRS score ≥ 3 | 211 (39.7) |